Table 1.
Patient characteristics.
| Total (n = 84) | |
|---|---|
|
Age, years Median (range) |
78 (47-91) |
| ECOG PS, n (%) | |
| 0–1 | 77 (84.3) |
| 2 | 7 (15.7) |
| Prostatectomy, n (%) | |
| No | 41 (48.8) |
| Yes | 43 (51.2) |
| Radical radiotherapy, n (%) | |
| No | 66 (78.6) |
| Yes | 18 (21.4) |
| Gleason score, n (%) | |
| <8 | 32 (38.1) |
| ≥8 | 33 (39.3) |
| Unknown/missing | 19 (22.6) |
| Bone metastases, n (%) | |
| No | 26 (31.0) |
| Yes | 58 (69.0) |
| Visceral metastases, n (%) | |
| No | 79 (94.0) |
| Yes | 5 (6.0) |
| Nodal metastases, n (%) | |
| No | 24 (40.0) |
| Yes | 50 (60.0) |
| Serum PSA, mg/l | |
| Median (range) | 9.64 (0.2-1555) |
| Serum LDH, n (%) | |
| <225 U/l | 55 (65.5) |
| ≥225a U/l | 13 (15.5) |
| Unknown/missing | 16 (19) |
| Hemoglobin, n (%) | |
| ≥12.5a g/l | 31 (36.9) |
| <12.5 g/l | 22 (26.2) |
| Unknown/missing | 31 (36.9) |
| ALP, n (%) | |
| <129 U/l | 23 (27.4) |
| ≥129a U/l | 6 (7.1) |
| Unknown/missing | 55 (65.5) |
| NLR, n (%) | |
| <3 | 35 (41.7) |
| ≥3 | 18 (21.4) |
| Unknown/missing | 31 (36.9) |
| SII, n (%) | |
| <535 | 30 (35.7) |
| ≥535 | 23 (27.4) |
| Unknown/missing | 31 (36.9) |
ALP alkaline phosphatase, ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, n number, R neutrophil-to-lymphocyte ratio, PS performance status, PSA prostate-specific antigen, SII systemic immune-inflammation index.
aUpper normal value.